These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3266957)

  • 21. Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
    Pickar D; Breier A; Kelsoe J
    Ann N Y Acad Sci; 1988; 537():339-46. PubMed ID: 2904783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of clonidine on central and peripheral catecholamine metabolism.
    Martin PR; Ebert MH; Gordon EK; Linnoila M; Kopin IJ
    Clin Pharmacol Ther; 1984 Mar; 35(3):322-7. PubMed ID: 6199153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain contribution to the haloperidol-induced increase in plasma homovanillic acid.
    Kendler KS; Heninger GR; Roth RH
    Eur J Pharmacol; 1981 May; 71(2-3):321-6. PubMed ID: 7250191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
    Konicki PE; Owen RR; Litman RE; Pickar D
    Life Sci; 1991; 48(14):1411-6. PubMed ID: 2008157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of debrisoquin on the excretion of catecholamine and octopamine metabolites in the rat and guinea pig.
    Edwards DJ; Ravitch J; Knopf S
    Biochem Pharmacol; 1985 Aug; 34(16):2911-6. PubMed ID: 3896245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects on brain catecholamines by debrisoquin.
    Maas JW; Hattox SE; Landis DH
    Biochem Pharmacol; 1979 Oct; 28(20):3153-6. PubMed ID: 117812
    [No Abstract]   [Full Text] [Related]  

  • 27. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method.
    Riddle MA; Jatlow PI; Anderson GM; Cho SC; Hardin MT; Cohen DJ; Leckman JF
    Neuropsychopharmacology; 1989 Jun; 2(2):123-9. PubMed ID: 2742727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of d-amphetamine on urinary metabolites of dopamine and norepinephrine in hyperactive boys.
    Shekim WO; Javaid J; Dekirmenjian H; Chapel JL; Davis JM
    Am J Psychiatry; 1982 Apr; 139(4):485-8. PubMed ID: 7065295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indomethacin prevents increased catecholamine turnover in rat brain following systemic endotoxin challenge.
    Masana MI; Heyes MP; Mefford IN
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(4):609-21. PubMed ID: 2236587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diurnal variation in plasma homovanillic acid level persists but the variation in 3-methoxy-4-hydroxyphenylglycol level is abolished under constant conditions.
    Sack DA; James SP; Doran AR; Sherer MA; Linnoila M; Wehr TA
    Arch Gen Psychiatry; 1988 Feb; 45(2):162-6. PubMed ID: 3337614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproducibility of plasma catecholamine metabolites in normal subjects.
    Amin F; Hashmi A; Stroe AE; Adebogun O; Densmore D; Knott PJ
    Biol Psychiatry; 1998 Feb; 43(3):233-5. PubMed ID: 9494706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of patients with the highest plasma catecholamine metabolite levels.
    Bowers MB; Swigar ME; Hoffman FJ; Goicoechea N
    Am J Psychiatry; 1988 Feb; 145(2):246-8. PubMed ID: 3422545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in saliva and plasma of healthy volunteers.
    Yang RK; Yehuda R; Holland DD; Knott PJ
    Biol Psychiatry; 1997 Nov; 42(9):821-6. PubMed ID: 9347131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
    Mazure CM; Nelson JC; Jatlow PI; Bowers MB
    Biol Psychiatry; 1991 Sep; 30(5):475-82. PubMed ID: 1932395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brain catecholamine metabolites and behavior in morphine withdrawal.
    Swann AC; Elsworth JD; Charney DS; Jablons DM; Roth RH; Redmond DE; Maas JW
    Eur J Pharmacol; 1982 Dec; 86(2):167-75. PubMed ID: 6297931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopaminergic contribution to cognitive sequence learning.
    Nagy O; Kelemen O; Benedek G; Myers CE; Shohamy D; Gluck MA; Kéri S
    J Neural Transm (Vienna); 2007; 114(5):607-12. PubMed ID: 17347774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reproducibility of the measurement of plasma noradrenergic and dopaminergic metabolites in normal subjects.
    Baker NJ; Adler LE; Waldo M; Gerhardt G; Drebing C; Cox B; Berry S; Phillips W; Freedman R
    Psychiatry Res; 1988 Feb; 23(2):119-30. PubMed ID: 3363020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline.
    Umene-Nakano W; Yoshimura R; Yoshii C; Hayashi K; Ikenouchi-Sugita A; Katsuki A; Hori H; Nakamura J
    Nicotine Tob Res; 2012 Apr; 14(4):486-9. PubMed ID: 22006914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Studies of catecholamine metabolism in schizophrenia/psychosis--I.
    Maas JW; Contreras SA; Miller AL; Berman N; Bowden CL; Javors MA; Seleshi E; Weintraub S
    Neuropsychopharmacology; 1993 Feb; 8(2):97-109. PubMed ID: 8471132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Plasma levels of MHPG, HVA and total 5-HIAA in depression. Preliminary study].
    Raucoules D; Levy C; Azorin JM; Bruno M; Valli M
    Encephale; 1992; 18(6):611-6. PubMed ID: 1285270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.